Current Firm
F-Prime Capital (fka Fidelity Biosciences)
Investments
1+ companies
Focus
Biotech, Digital Health
Stephen Knight is President and Managing Partner at F-Prime Capital, formerly known as Fidelity Biosciences. In this leadership role, he oversees the firm's investment strategy and portfolio management across multiple high-growth sectors. Knight focuses on identifying and nurturing opportunities in biotech, digital health, Web3, and fintech, leveraging deep industry expertise to support emerging companies through critical growth phases. His investment track record includes notable backing of SnapDocs, demonstrating his ability to recognize transformative business models. With his strategic vision and sector knowledge, Knight has established himself as a prominent figure in venture capital, particularly in the life sciences and financial technology spaces.
Stephen Knight is a President and Managing Partner, F-Prime Capital (fka Fidelity Biosciences) at F-Prime Capital (fka Fidelity Biosciences), based in Boston, MA.
Stephen's investment focus spans Biotech, Digital Health, Web3, Fintech, primarily investing at the Pre-Seed, Seed, Series A, Series B+ stages. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
Notable investments include SnapDocs. These investments span Biotech and Digital Health.
Stephen Knight is a President and Managing Partner, F-Prime Capital (fka Fidelity Biosciences) at F-Prime Capital (fka Fidelity Biosciences), based in Boston, MA. Their investment focus includes Biotech, Digital Health, Web3.
Stephen Knight focuses on investments in Biotech, Digital Health, Web3, Fintech through F-Prime Capital (fka Fidelity Biosciences). These focus areas reflect their domain expertise and the types of startups they actively seek to back.
Stephen Knight's notable portfolio investments include SnapDocs. These companies span multiple sectors and stages, reflecting a track record of identifying high-potential startups.
Stephen Knight is currently at F-Prime Capital (fka Fidelity Biosciences), headquartered in Boston, MA, serving as President and Managing Partner, F-Prime Capital (fka Fidelity Biosciences).